(RGNX) Regenxbio - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 368m USD | Total Return: -35.7% in 12m
Avg Turnover: 10.3M
Qual. Beats: -2
Rev. Trend: 53.4%
Qual. Beats: -2
Warnings
Interest Coverage Ratio -5.7 is critical
Altman Z'' -13.45 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform. This platform utilizes adeno-associated virus (AAV) vectors to deliver functional genes to cells affected by genetic defects. The company’s pipeline targets high-need indications, including wet age-related macular degeneration, Duchenne muscular dystrophy, and mucopolysaccharidosis.
The company employs a dual-revenue business model, advancing its own internal drug candidates while simultaneously licensing its NAV Technology Platform to third-party pharmaceutical firms. Gene therapy development typically involves high research and development costs but offers potential long-term value through high-barrier-to-entry intellectual property and orphan drug designations. REGENXBIO maintains strategic partnerships with industry leaders such as AbbVie and Nippon Shinyaku to facilitate global development and commercialization.
Reviewing the historical performance of these licensing agreements on ValueRay can provide deeper insight into the companys capital structure. REGENXBIO operates within the biotechnology sector, where clinical trial milestones and regulatory approvals serve as the primary catalysts for valuation shifts.
- Clinical data readouts for ABBV-RGX-314 determine partnership milestone payments from AbbVie
- Regulatory approval timelines for RGX-121 impact first commercial product launch revenue
- NAV Technology Platform licensing fees provide non-dilutive capital and validation
- Competitive landscape in Duchenne muscular dystrophy affects RGX-202 market share potential
- High research and development expenditures necessitate ongoing capital raises or partnerships
| Net Income: -290.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.71 > 0.02 and ΔFCF/TA -49.08 > 1.0 |
| NWC/Revenue: 131.4% < 20% (prev 131.8%; Δ -0.36% < -1%) |
| CFO/TA -0.68 > 3% & CFO -233.8m > Net Income -290.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.4m) vs 12m ago 1.93% < -2% |
| Gross Margin: -0.14% > 18% (prev 76.54%; Δ -76.67% > 0.5%) |
| Asset Turnover: 21.09% > 50% (prev 31.92%; Δ -10.83% > 0%) |
| Interest Coverage Ratio: -5.69 > 6 (EBIT TTM -256.7m / Interest Expense TTM 45.1m) |
| A: 0.34 (Total Current Assets 186.5m - Total Current Liabilities 71.1m) / Total Assets 341.9m |
| B: -3.56 (Retained Earnings -1.22b / Total Assets 341.9m) |
| C: -0.62 (EBIT TTM -256.7m / Avg Total Assets 416.4m) |
| D: 0.07 (Book Value of Equity 21.1m / Total Liabilities 320.8m) |
| Altman-Z'' = -13.45 = D |
| DSRI: 0.94 (Receivables 10.0m/19.2m, Revenue 87.8m/156.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.03 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 0.56 (Revenue 87.8m / 156.7m) |
| TATA: -0.16 (NI -290.0m - CFO -233.8m) / TA 341.9m) |
| Beneish M = -3.39 (Cap -4..+1) = AA |
As of June 09, 2026, the stock is trading at USD 6.13 with a total of 1,198,039 shares traded.
Over the past week, the price has changed by -14.15%,
over one month by -41.90%,
over three months by -40.94% and
over the past year by -35.68%.
Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.2 | 294.5% |
P/S = 4.1383
P/B = 17.19
P/EG = 0.26
Revenue TTM = 87.8m USD
EBIT TTM = -256.7m USD
EBITDA TTM = -241.2m USD
Long Term Debt = 63.2m USD (estimated: total debt 71.1m - short term 7.87m)
Short Term Debt = 7.87m USD (from shortTermDebt, last quarter)
Debt = 71.1m USD (from shortLongTermDebtTotal, last quarter) (leases 71.1m already included)
Net Debt = -21.1m USD (calculated: Debt 71.1m - CCE 92.1m)
Enterprise Value = 346.5m USD (367.6m + Debt 71.1m - CCE 92.1m)
Interest Coverage Ratio = -5.69 (Ebit TTM -256.7m / Interest Expense TTM 45.1m)
EV/FCF = -1.43x (Enterprise Value 346.5m / FCF TTM -242.5m)
FCF Yield = -69.98% (FCF TTM -242.5m / Enterprise Value 346.5m)
FCF Margin = -276.1% (FCF TTM -242.5m / Revenue TTM 87.8m)
Net Margin = -330.2% (Net Income TTM -290.0m / Revenue TTM 87.8m)
Gross Margin = -0.14% ((Revenue TTM 87.8m - Cost of Revenue TTM 87.9m) / Revenue TTM)
Gross Margin QoQ = -73.22% (prev 80.46%)
Tobins Q-Ratio = 1.01 (Enterprise Value 346.5m / Total Assets 341.9m)
Interest Expense / Debt = 63.53% (Interest Expense 45.1m / Debt 71.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -202.8m (EBIT -256.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.02 (Total Current Assets 186.5m / Total Current Liabilities 92.3m)
Debt / Equity = 3.37 (Debt 71.1m / totalStockholderEquity, last quarter 21.1m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -21.1m / EBITDA -241.2m)
Debt / FCF = 0.09 (negative FCF - burning cash) (Net Debt -21.1m / FCF TTM -242.5m)
Total Stockholder Equity = 124.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.65% (Net Income -290.0m / Total Assets 341.9m)
RoE = -232.5% (Net Income TTM -290.0m / Total Stockholder Equity 124.7m)
RoCE = -136.6% (out of range, set to none) (EBIT -256.7m / Capital Employed (Equity 124.7m + L.T.Debt 63.2m))
RoIC = -73.94% (negative operating profit) (NOPAT -202.8m / Invested Capital 274.3m)
WACC = 10.84% (E(367.6m)/V(438.6m) * Re(12.93%) + (debt cost/tax rate unavailable))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 8.10%
[DCF] Fair Price = unknown (Cash Flow -242.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.16 | # QB: -2
Revenue Correlation: 53.42 | Revenue CAGR: 19.01% | SUE: -2.08 | # QB: -2
EPS current Quarter (2026-06-30): EPS=0.34 | Chg30d=+244.30% | Revisions=-14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-1.48 | Chg30d=-32.99% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=-2.85 | Chg30d=-42.52% | Revisions=+20% | GrowthEPS=+24.2% | GrowthRev=+38.5%
EPS next Year (2027-12-31): EPS=-2.52 | Chg30d=-14.78% | Revisions=+20% | GrowthEPS=+11.5% | GrowthRev=+15.4%
[Analyst] Revisions Ratio: -25%